To assess the efficacy and safety of CTX and moderate‐dosage cytarabine (Ara‐C) as induction chemotherapy in newly diagnosed adult AML, 40 patients were enrolled to receive CTX (20 mg/kg/d) for 4 consecutive days and Ara‐C for 3 (1 g/m2 q12h, CA4+3) or 5 (1 g/m2 qd, CA4+5) days. This evidence concerns the gene CA4 and acute myeloid leukemia.